CD274 and neoplasm: Although durvalumab improved PFS and OS in tumours with PD-L1 ≥ 1%, in the 148 patients with PD-L1 < 1%, durvalumab neither improved PFS (HR 0.73; 95%CI: 0.48–1.11) nor OS (HR: 1.14, 95%CI: 0.71–1.84) [69].